Maximize merger arbitrage growth returns

Out maneuver the market and identify potential regulatory hurdles for mergers and acquisitions with MLex. Our exclusive market insight, analysis and commentary covers deals from pre-notification through notification, review and approval.

The world's leading hedge funds use the MLex DealRisk service to analyze deals through notification, review, approval and compliance with daily case updates on M&A clearance.

As reported first by MLex

Like to read the full text of these, or any other MLex insights? Request a trial subscription via the form at the bottom of the page.

Bayer-Monsanto deal hasn't received staff recommendation at US DOJ; decision expected by early April

2 March 18

Qualcomm still to refile NXP deal to China’s Mofcom as deadline looms

12 April 2018

Tronox, Cristal point to Chinese competition in EU hearing on titanium-dioxide deal

11 April 2018

Key Deals

Our coverage includes exclusive insight and analysis on the following key deals around the globe.

USA

United States of America

AT&T/Time Warner
Bayer/Monsanto
Linde/Praxair
UTC/Rockwell
CVS/Aetna
Sinclair/Tribune
Tronox/Cristal
Fresenius/Akorn
Fresenius/NXStage
Northrop Grumman/Orbital ATK
Cigna/Express Scripts
Disney/21st Century Fox
Westrock/KapStone
Servier/Shire

EU

The EU & UK

Bayer/Monsanto
Linde/Praxair
UTC/Rockwell
Tronox/Cristal
Disney/21st Century Fox
Arcelor/Ilva
Solvay/BASF
Apple/Shazam
Servier/Shire

Asia

Asia

Qualcomm/NXP
Bain Capital/Toshiba Memory
Linde/Praxair
UTC/Rockwell
Essilor/Luxottica

Latin America

Latin America

Linde/Praxair
UTC/Rockwell
Prysmian/General Cable
Servier/Shire
Fibria/Suzano

Request a Free Trial

At MLex we take your privacy seriously. As detailed in our Privacy Policy we will use your personal information to administer account and provide the products and services that you have requested from us.

We may contact you with details of other LexisNexis products, services and events we believe you may be interested in as a result of your relationship with us. You can amend your communication preferences via our MLex Preference Center.

Looking for breaking news and to review regulatory implications for specific deals? Complete the form to request a free, limited trial to MLex.